Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Matthew Fust Biography and Net Worth

Director of Atara Biotherapeutics

Mr. Fust has served as a member of the Ultragenyx Board since January 2014. Currently, he is a Board member and an advisor to life sciences companies. Mr. Fust served as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. from January 2009 until January 2014, when he retired. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the Board of Directors of Atara Biotherapeutics, Inc., and Crinetics Pharmaceuticals, Inc. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

What is Matthew K. Fust's net worth?: The estimated net worth of Matthew K. Fust is at least $13,247.68 as of March 20th, 2024. Mr. Fust owns 18,536 shares of Atara Biotherapeutics stock worth more than $13,248 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Fust may own. Learn More about Matthew K. Fust's net worth.
How do I contact Matthew K. Fust?: The corporate mailing address for Mr. Fust and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Matthew K. Fust's contact information.
Has Matthew K. Fust been buying or selling shares of Atara Biotherapeutics?: Matthew K. Fust has not been actively trading shares of Atara Biotherapeutics during the last ninety days. Most recently, Matthew K. Fust sold 13,354 shares of the business's stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $19.50, for a transaction totalling $260,403.00. Learn More on Matthew K. Fust's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 184,801 shares worth more than $237,993.35. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 3/4/2024.

Matthew K. Fust Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/4/2021	Sell	13,354	$19.50	$260,403.00
5/14/2018	Sell	12,286	$43.57	$535,301.02	19,820

Matthew K. Fust Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $0.71

$0.69

$0.74

50 Day Range

MA: $0.72

$0.60

$0.84

2 Week Range

Now: $0.71

$0.20

$3.02

Volume

697,941 shs

Average Volume

2,695,873 shs

Market Capitalization

$85.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Pentagon contract could send this $2 AI stock soaring

From Behind the Markets | Ad

Get all the info here >>>